| Vol. 10.15 – 19 April, 2022 |
| |
|
|
| Researchers demonstrated mux-seq as a systematic approach to characterize cellular composition, identify transcriptional signatures, and annotate genetic variants associated with systemic lupus erythematosus. [Science] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Scientists found that a combination of interferon alpha and anti-PD-1-based immunotherapy resulted in enhanced antitumor activity in unresectable hepatocellular carcinoma patients. [Cancer Discovery] |
|
|
|
| The authors reported that the hallmarks of tumor recognition in ovarian cancer-infiltrating T cells were primarily restricted to tissue-resident memory cells. [Cancer Cell] |
|
|
|
| Investigators reported on the successful adoptive transfer of autologous, ex vivo expanded regulatory T cells in a patient with refractory ulcerative colitis and associated primary sclerosing cholangitis, for which effective therapy is currently not available. [Gut] |
|
|
|
| Researchers investigated whether resting CD8+ memory T cells persisting after cleared infection with attenuated lymphocytic choriomeningitis virus could initiate immune responses directed against cognate self-antigen in the central nervous system. [Science Translational Medicine] |
|
|
|
| The authors demonstrated that, although IL-10 itself is anti-inflammatory, IL-10+ functional regulatory B cells in patients with systemic lupus erythematosus displayed aggressive inflammatory features. [Signal Transduction and Targeted Therapy] |
|
|
|
| Scientists suggested distinct differentiation potential of CD62L+ and CD62L– innate lymphoid cells (ILCs) between tissue microenvironments and identified that manipulation of these cells was a possible approach to restore tissue-immune homeostasis. [Science Immunology] |
|
|
|
| Investigators single-cell–profiled CD45+ immune cell transcriptomes from skin samples of 31 patients and revealed active proliferative expansion of regulatory T and tissue-resident memory T cells components and universal T cell exhaustion in human rashes, with a relative attenuation of antigen-presenting cells. [Science Immunology] |
|
|
|
| The authors addressed whether adenomatous polyposis coli (APC) played a role in T lymphocyte migration. Using a series of cell biology tools, they unveiled that T cells from familial adenomatous polyposis patients carrying APC mutations displayed impaired adhesion and motility in constrained environments. [Science Advances] |
|
|
|
| Scientists showed single-cell T cell receptor (TCR) coupled with RNA sequencing of CD3+ T cells from 13 patients, sampled before and after alemtuzumab treatments. Effector memory T cells and loss of TCR repertoire diversity were prevalent in T cell large granular lymphocyte leukemia. [Nature Communications] |
|
|
|
| The authors showed that broadening the number of neoantigen-reactive CD8+ T cell populations between pre-treatment to three weeks post-treatment distinguished patients with controlled disease compared to patients with progressive disease in metastatic urothelial carcinoma treated with PD-L1-blockade. [Nature Communications] |
|
|
|
| Researchers showed, by using 16 different stimuli in vitro, that activated dendritic cells in human blood were phenotypically and functionally dichotomous, and pure cultures of type 2 conventional dendritic cells acquired these states upon appropriate stimuli. [Nature Communications] |
| |
|
|
|
| The authors present the intricate mechanisms through which dysregulated non-coding RNAs control resistance to the four major types of cancer therapies. [Signal Transduction and Targeted Therapy] |
|
|
|
| Investigators summarize preclinical and early phase clinical trial research of oncometabolism-based therapeutics that may augment immunotherapy by exploiting the biochemical and genetic underpinnings of brain tumors. [Oncogene] |
|
|
|
| Exploiting the wide spectrum of diacylglycerol signals from an integrated perspective could underscore meaningful advances in targeted cancer therapy. [Science Signaling] |
|
|
|
|
| BriaCell Therapeutics Corp., a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, announced that the US FDA has granted Fast Track status to BriaCell’s lead candidate, Bria-IMT™, for the treatment of metastatic breast cancer. [BriaCell Therapeutics Corp.] |
|
|
|
| Bristol Myers Squibb and Nektar have read the last rites to their huge, failed cancer collaboration. With two more late-stage trials failing, the partners have ended clinical development of a combination they once saw as the future of immunooncology. [Fierce Biotech] |
|
|
|
|
| June 12 – 16, 2022 Ascona, Switzerland |
|
|
|
|
|
| Fred Hutchinson Cancer Center – Seattle, Washington, United States |
|
|
|
| The University of British Columbia – Vancouver, British Columbia, Canada |
|
|
|
| Oklahoma Medical Research Foundation – Oklahoma City, Oklahoma, United States |
|
|
|
| University Hospital Carl Gustav Carus Dresden- Dresden, Germany |
|
|
|
| Luxembourg Institute of Health – Luxembourg, Luxembourg |
|
|
|
|